Science Explorer Back to mapMap
Discussion
Company · Leiden · Netherlands

Astellas Pharma (Netherlands)

In research, Astellas Pharma (Netherlands) stands highest in Medicine (#5,228 of 14,558 worldwide) and Health Sciences (#6,275 of 16,688 worldwide), over all time.

astellas.com/en/index.htmlROR OpenAlex
World rank, all time
#24,683
of 34,923
Rank in Netherlands
#309
of 407
Research works
200
▼ 61% vs 2018-21
Citations
4.7k
23.5 per fractional work
Top-10% rate
10.7%
all institutions 10.0%
vs its own fields
1.09×
1.00× is exactly expected
Open access
43%
world 40%
International
76%
world 18%
Astellas Pharma (Netherlands)

What is Astellas Pharma (Netherlands) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
MedicineField #5,228 of 14,558 15.0%134
Health SciencesDomain #6,275 of 16,688 14.8%137

Each strip is that field's whole ranked pool, with the notch where Astellas Pharma (Netherlands) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Astellas Pharma (Netherlands) work in?

In all years, 68% of research at Astellas Pharma (Netherlands) is in Health Sciences, 16% in Life Sciences. Its largest fields are Medicine (67%), Biochemistry, Genetics and Molecular Biology (8%), Economics, Econometrics and Finance (5%). It does 2.8× the world's share of Health Sciences.

Health Sciences: 137 fractional works · 68.5% of its workMedicine: 134 fractional works · 67.1% of its workUrology: 18 fractional works · 8.9% of its workEpidemiology: 12 fractional works · 5.9% of its workPulmonary and Respiratory Medicine: 12 fractional works · 5.8% of its workHematology: 10 fractional works · 5.1% of its workEndocrinology, Diabetes and Metabolism: 10 fractional works · 4.8% of its workSurgery: 10 fractional works · 4.8% of its workRheumatology: 9 fractional works · 4.5% of its workOncology: 8 fractional works · 4.2% of its workCardiology and Cardiovascular Medicine: 5 fractional works · 2.7% of its workPhysiology: 5 fractional works · 2.6% of its workNephrology: 4 fractional works · 2.0% of its workPharmacology: 3 fractional works · 1.7% of its workRadiology, Nuclear Medicine and Imaging: 3 fractional works · 1.6% of its workInfectious Diseases: 3 fractional works · 1.4% of its workNeurology: 2 fractional works · 1.2% of its workPsychiatry and Mental health: 2 fractional works · 1.1% of its workGenetics: 2 fractional works · 1.1% of its workPediatrics, Perinatology and Child Health: 2 fractional works · 0.9% of its workReproductive Medicine: 2 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 2 fractional works · 0.8% of its workGastroenterology: 1 fractional works · 0.6% of its workTransplantation: 1 fractional works · 0.6% of its workAnesthesiology and Pain Medicine: 1 fractional works · 0.5% of its workDermatology: 1 fractional works · 0.5% of its workPathology and Forensic Medicine: 1 fractional works · 0.5% of its workObstetrics and Gynecology: 1 fractional works · 0.5% of its workBiochemistry: 1 fractional works · 0.4% of its workHepatology: 1 fractional works · 0.3% of its workOphthalmology: 1 fractional works · 0.3% of its workInternal Medicine: 0 fractional works · 0.3% of its workEmergency Medicine: 0 fractional works · 0.2% of its workComplementary and alternative medicine: 0 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 0.5% of its workHealth Professions: 2 fractional works · 0.9% of its workGeneral Health Professions: 1 fractional works · 0.5% of its workSmaller subfields together: 1 fractional works · 0.4% of its workVeterinary: 1 fractional works · 0.3% of its workSmall Animals: 1 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workNursing: 0 fractional works · 0.2% of its workLife Sciences: 32 fractional works · 16.1% of its workBiochemistry, Genetics and Molecular Biology: 16 fractional works · 8.1% of its workMolecular Biology: 8 fractional works · 3.8% of its workCancer Research: 4 fractional works · 2.0% of its workGenetics: 3 fractional works · 1.4% of its workBiotechnology: 1 fractional works · 0.4% of its workBiophysics: 0 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 0.4% of its workPharmacology, Toxicology and Pharmaceutics: 7 fractional works · 3.6% of its workPharmacology: 3 fractional works · 1.7% of its workToxicology: 2 fractional works · 1.1% of its workPharmaceutical Science: 1 fractional works · 0.7% of its workImmunology and Microbiology: 4 fractional works · 2.1% of its workImmunology: 3 fractional works · 1.7% of its workVirology: 1 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNeuroscience: 4 fractional works · 2.0% of its workCellular and Molecular Neuroscience: 2 fractional works · 1.0% of its workSensory Systems: 1 fractional works · 0.6% of its workSmaller subfields together: 1 fractional works · 0.4% of its workAgricultural and Biological Sciences: 1 fractional works · 0.3% of its workPlant Science: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 15 fractional works · 7.7% of its workEconomics, Econometrics and Finance: 10 fractional works · 4.8% of its workEconomics and Econometrics: 10 fractional works · 4.8% of its workSocial Sciences: 2 fractional works · 1.0% of its workLaw: 1 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.7% of its workBusiness, Management and Accounting: 1 fractional works · 0.7% of its workManagement of Technology and Innovation: 1 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPsychology: 1 fractional works · 0.7% of its workSocial Psychology: 1 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.1% of its workDecision Sciences: 1 fractional works · 0.5% of its workManagement Science and Operations Research: 1 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPhysical Sciences: 15 fractional works · 7.7% of its workMathematics: 5 fractional works · 2.4% of its workStatistics and Probability: 5 fractional works · 2.4% of its workEngineering: 4 fractional works · 1.9% of its workAerospace Engineering: 2 fractional works · 0.8% of its workBiomedical Engineering: 1 fractional works · 0.6% of its workElectrical and Electronic Engineering: 1 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workComputer Science: 2 fractional works · 1.2% of its workComputational Theory and Mathematics: 1 fractional works · 0.5% of its workComputer Networks and Communications: 1 fractional works · 0.4% of its workArtificial Intelligence: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workChemistry: 2 fractional works · 1.2% of its workSpectroscopy: 1 fractional works · 0.5% of its workOrganic Chemistry: 1 fractional works · 0.5% of its workAnalytical Chemistry: 0 fractional works · 0.2% of its workMaterials Science: 1 fractional works · 0.5% of its workEnvironmental Science: 1 fractional works · 0.3% of its workEarth and Planetary Sciences: 0 fractional works · 0.1% of its workPhysics and Astronomy: 0 fractional works · 0.1% of its workALL ITS WORKAstellas Pharma(Netherlands)200fractional works, all years
Life Sciences16%Physical Sciences8%Health Sciences68%Social Sciences8%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 22 fields, with their numbers
    1. Medicine13467.1%
    2. Health Professions20.9%
    3. Veterinary10.3%
    4. Nursing00.2%
    1. Biochemistry, Genetics and Molecular Biology168.1%
    2. Pharmacology, Toxicology and Pharmaceutics73.6%
    3. Immunology and Microbiology42.1%
    4. Neuroscience42.0%
    5. Agricultural and Biological Sciences10.3%
    1. Economics, Econometrics and Finance104.8%
    2. Social Sciences21.0%
    3. Business, Management and Accounting10.7%
    4. Psychology10.7%
    5. Decision Sciences10.5%
    1. Mathematics52.4%
    2. Engineering41.9%
    3. Computer Science21.2%
    4. Chemistry21.2%
    5. Materials Science10.5%
    6. Environmental Science10.3%
    7. Earth and Planetary Sciences00.1%
    8. Physics and Astronomy00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.34× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 3.40× its world share, 1 worksImmunology and Micro…Neuroscience: 0.59× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 1.24× its world share, 0 worksPharmacology, Toxico…Computer Science: 0.28× its world share, 0 worksComputer ScienceEngineering: 0.01× its world share, 0 worksEngineeringEnvironmental Science: 0.11× its world share, 0 worksEnvironmental ScienceMathematics: 3.23× its world share, 1 worksMathematicsPhysics and Astronomy: 0.08× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.59× its world share, 0 worksHealth ProfessionsMedicine: 3.35× its world share, 13 worksMedicineBusiness, Management and Accounting: 0.13× its world share, 0 worksBusiness, Management…Decision Sciences: 0.61× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 2.17× its world share, 1 worksEconomics, Econometr…Psychology: 1.39× its world share, 1 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 3.4×. Every wedge is a field page.

All 15 fields, with their numbers
  1. Immunology and Microbiology3.40×1 works
  2. Medicine3.35×13 works
  3. Mathematics3.23×1 works
  4. Biochemistry, Genetics and Molecular Biology2.34×2 works
  5. Economics, Econometrics and Finance2.17×1 works
  6. Psychology1.39×1 works
  7. Pharmacology, Toxicology and Pharmaceutics1.24×0 works
  8. Decision Sciences0.61×0 works
  9. Neuroscience0.59×0 works
  10. Health Professions0.59×0 works
  11. Computer Science0.28×0 works
  12. Business, Management and Accounting0.13×0 works
  13. Environmental Science0.11×0 works
  14. Physics and Astronomy0.08×0 works
  15. Engineering0.01×0 works

Who are the top researchers at Astellas Pharma (Netherlands)?

Ranked on the quality score, De Phung, Arwin M. Ridder and Ted Drogendijk lead among researchers whose main affiliation is Astellas Pharma (Netherlands).

  1. 1 De Phung Netherlands · #375,000 worldwide 6k citations · 55 works
  2. 2 Arwin M. Ridder Netherlands · #378,364 worldwide 2.4k citations · 32 works
  3. 3 Ted Drogendijk Netherlands · #599,238 worldwide 2.2k citations · 31 works
  4. 4 Benoît Baron Netherlands · #669,720 worldwide 3.2k citations · 34 works
  5. 5 Rob van Maanen Netherlands · #682,302 worldwide 1k citations · 29 works
  6. 6 Taoufik Ouatas Netherlands · #847,288 worldwide 2.3k citations · 51 works
  7. 7 Marten J. Heeringa Netherlands · #1,343,981 worldwide 1.8k citations · 45 works
  8. 8 John Meijer Netherlands · #1,349,925 worldwide 2.4k citations · 31 works
  9. 9 Monique Klaver Netherlands · #1,383,200 worldwide 506 citations · 30 works
  10. 10 Steve van Os Netherlands · #1,387,245 worldwide 1.4k citations · 20 works
All ranked researchers at Astellas Pharma (Netherlands)

What are the most cited papers from Astellas Pharma (Netherlands)?

The most cited paper from Astellas Pharma (Netherlands) is "ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer" (Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak et al., 2019), with 1,239 citations. Next come "Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial" (429) and "Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study" (426).

Most cited papers
#PaperReleasedCitations
1 ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak et al. · Journal of Clinical Oncology Open access 22 Jul 2019 1,239
2 Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology 6 Nov 2012 429
3 Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study Tomasz M. Beer et al. · European Urology Open access 29 Jul 2016 426
4 Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access 10 Jan 2018 390
5 Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity Dan H. Barouch, Maria Grazia Pau, Jerome H. H. V. Custers et al. · The Journal of Immunology Open access May 2004 388
All 61 most cited papers, with filters and sorting

Which keywords describe research at Astellas Pharma (Netherlands)?

By fractional works in all years, weighted toward what it does more of than the world: Urinary Incontinence, Quality of Life, Epidemiology, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Cardiovascular Disease, Immunotherapy and Hormone Therapy.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Epidemiology28▲ 3.5×44 topics
  2. Urinary Incontinence25▲ 138×2 topics
  3. Quality of Life21▲ 8.0×11 topics
  4. Benign Prostatic Hyperplasia17▲ 207×1 topic
  5. Lower Urinary Tract Symptoms17▲ 207×1 topic
  6. Cardiovascular Disease15▲ 6.8×17 topics
  7. Immunotherapy11▲ 8.7×12 topics
  8. Hormone Therapy11▲ 52×3 topics
  9. Biomarkers11▲ 8.8×9 topics
  10. Cancer Treatment10▲ 20×4 topics
  11. Chronic Kidney Disease10▲ 21×5 topics
  12. Prostate Cancer10▲ 33×4 topics
  13. Surgical Treatment10▲ 24×3 topics
  14. Heart Failure9▲ 10×6 topics
  15. Clinical Trials9▲ 7.3×10 topics
  16. Stroke9▲ 28×4 topics
  17. Neuroprotection9▲ 11×6 topics
  18. Anemia8▲ 37×3 topics
  19. Antimicrobial Resistance8▲ 16×4 topics
  20. Rehabilitation8▲ 11×4 topics
  21. Pelvic Floor Dysfunction8▲ 81×1 topic
  22. Pelvic Organ Prolapse8▲ 81×1 topic
  23. Iron Deficiency8▲ 69×2 topics
  24. Treatment Guidelines8▲ 18×3 topics
  25. Catheter-Associated Infections7▲ 104×1 topic
  26. Urinary Tract Infections7▲ 81×1 topic
  27. Guidelines7▲ 7.2×6 topics
  28. Genetic Mutations7▲ 6.4×5 topics
  29. Metabolic Syndrome7▲ 3.9×12 topics
  30. Erythropoiesis-Stimulating Agents6▲ 223×1 topic
  31. Genomic Profiling6▲ 33×2 topics
  32. Hypoxia-Inducible Factors6▲ 223×1 topic
  33. Androgen Receptor6▲ 34×1 topic
  34. Metastatic Prostate Cancer6▲ 71×1 topic
  35. Chemotherapy6▲ 4.1×10 topics
  36. Cost-effectiveness Analysis6▲ 37×1 topic
  37. Health Utility Measures6▲ 37×1 topic
  38. Diabetes5▲ 5.3×11 topics
  39. Clinical Guidelines5▲ 8.5×7 topics
  40. Nociception5▲ 36×2 topics

Which research topics does Astellas Pharma (Netherlands) publish most on?

By volume in 2022-now: BRCA gene mutations in cancer, Menopause: Health Impacts and Treatments, Health Systems, Economic Evaluations, Quality of Life and Erythropoietin and Anemia Treatment.

BRCA gene mutations in c…1BRCA gene mutations in cancer: 1 fractional worksMenopause: Health Impact…1Menopause: Health Impacts and Treatments: 1 fractional worksHealth Systems, Economic…1Health Systems, Economic Evaluations, Quality of Life: 1 fractional worksErythropoietin and Anemi…1Erythropoietin and Anemia Treatment: 1 fractional worksBladder and Urothelial Cancer Treatments: 1 fractional worksHormonal and reproductive studies: 0 fractional worksUrinary Bladder and Pros…0Urinary Bladder and Prostate Research: 0 fractional worksBiosimilars and Bioanalytical Methods: 0 fractional worksDialysis and Renal Disease Management: 0 fractional worksComputational Drug Discovery Methods: 0 fractional works
GeneticsEndocrinology, Diabetes and MetabolismEconomics and EconometricsHematology5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 BRCA gene mutations in cancer Genetics 1 works
  2. 2 Menopause: Health Impacts and Treatments Endocrinology, Diabetes and Metabolism 1 works
  3. 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
  4. 4 Erythropoietin and Anemia Treatment Hematology 1 works
  5. 5 Bladder and Urothelial Cancer Treatments Surgery 1 works
  6. 6 Hormonal and reproductive studies Endocrinology, Diabetes and Metabolism 0 works
  7. 7 Urinary Bladder and Prostate Research Urology 0 works
  8. 8 Biosimilars and Bioanalytical Methods Immunology 0 works
  9. 9 Dialysis and Renal Disease Management Nephrology 0 works
  10. 10 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available42.8%not open57.2%

World: 40% of research is openly available.

with international co-authors76.1%domestic only23.9%

World: 18% is written across borders.

How has Astellas Pharma (Netherlands)'s research output changed?

Output in 2022-2025 was 61% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Astellas Pharma (Netherlands) as a percentage of every work published that year, 0.000084% in 2024.

still counting0.00020%0.00040%0.00060%Astellas Pharma (Netherlands)0.000059% in 20251990200020102020

Fractional works of Astellas Pharma (Netherlands) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Leiden

All research institutions in Leiden

Share Astellas Pharma (Netherlands)'s ranking

Astellas Pharma (Netherlands) on Science Explorer

A card with Astellas Pharma (Netherlands)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Astellas Pharma (Netherlands). Posts are plain text and can be reported.